Interstitial Cystitis Market Insights, Epidemiology and Market Forecast-2030

Albany, NY -- (SBWire) -- 04/15/2020 --Interstitial Cystitis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Interstitial Cystitis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
- The total Interstitial Cystitis prevalent population in the seven major markets was approximately 8,517,779 in 2017.
- The gender-specific prevalent population of Interstitial Cystitis in the United States was 1,503,306 cases for male and 3,496,794 cases for female in 2017.
- A higher Interstitial Cystitis prevalence was around 5,000,101 cases in the United States in 2017.

Key benefits of the report
1. Interstitial Cystitis market report covers a descriptive overview and comprehensive insight of the Interstitial Cystitis epidemiology and Interstitial Cystitis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Interstitial Cystitis market report provides insights on the current and emerging therapies.
3. Interstitial Cystitis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Interstitial Cystitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market.

Request for sample pages

The current Interstitial Cystitis therapeutic landscape in the US is divided into mainly two categories: monotherapy and combination therapy. These are further classified based on the route of administration of the drug as oral therapies, intravesical instillations, and other treatment options. Oral regimens are used either as first-line or second-line therapies for Interstitial Cystitis.

Among oral therapies, different classes of medication are used. Currently, there is no cure available for Interstitial Cystitis, but many treatments offer some relief, either on their own or in combination. Interstitial Cystitis treatment is aimed at relieving pain and reducing inflammation. The two main approaches are oral medications and bladder instillations—drugs that are introduced into the bladder by catheter and held for 15 min.

Interstitial Cystitis market is dominated by various off-label drugs (painkillers, antibiotic, anticonvulsant, antidepressants, antiepileptics, antihistamines, immunosuppressants, and L-arginine). The drug approved by USFDA, which is administered orally to patients suffering from Interstitial Cystitis is Elmiron.

The other Interstitial Cystitis treatment options include physical therapy, nerve stimulation techniques (transcutaneous electrical nerve stimulation, sacral nerve stimulation), and surgery (fulguration, resection and bladder augmentation).

The launch of the emerging therapies is expected to significantly impact Interstitial Cystitis treatment scenario in the upcoming years:-
Drugs covered
1. KRP-116D
2. SI-722
3. LP-08

And many others

The key players in Interstitial Cystitis market are:
1. Kyorin Holdings
2. Seikagaku Corporation
3. Lipella Pharmaceuticals

And many others

Table of contents
1. Key Insights

2. Executive Summary of Interstitial Cystitis

3. Interstitial Cystitis Market Overview at a Glance

4. Interstitial Cystitis Disease Background and Overview

5. Interstitial Cystitis Epidemiology and Patient Population

6. Country Wise-Epidemiology of Interstitial Cystitis

6.1. United States

6.2. EU5 Countries

6.2.1. Assumptions and Rationale

6.2.2. Germany

6.2.3. France

6.2.4. Italy

6.2.5. Spain

6.2.6. United Kingdom

6.3. Japan

7. Interstitial Cystitis Treatment Algorithm, Current Treatment, and Medical Practices

8. Unmet Needs

9. Interstitial Cystitis Marketed Drugs

9.1. Elmiron: Janssen Pharmaceutical

10. Instillations

10.1. RIMSO-50: Mylan Pharmaceutical

10.2. Cystistat: Bioniche Life Sciences Inc

10.3. Gepan instill: Pohl-Boskamp GmbH

10.4. Uracyst: Stellar Pharmaceuticals

10.5. iAluRil: Aspire Pharma

11. Interstitial Cystitis Emerging Therapies

11.1. Key Cross Competition

11.2. KRP-116D: Kyorin Holdings

11.3. SI-722: Seikagaku Corporation

11.4. LP-08: Lipella Pharmaceuticals

12. Interstitial Cystitis 7 Major Market Analysis

13. The United States Market Outlook

13.1. United States Market Size

14. EU-5 Countries: Market Outlook

14.1. Germany

14.2. France

14.3. Italy

14.4. Spain

14.5. United Kingdom

15. Japan: Market Outlook

16. Access and Reimbursement

17. Market Drivers

18. Market Barriers

19. SWOT Analysis

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight